Weight-loss drugs could prevent fatal complications from heart attacks, UK study finds
Latest research based on animal model trials shows GLP-1 drugs may prevent problem of ‘no-reflow’ in recovery

Weight-loss drugs could help people who have had a heart attack avoid suffering potentially fatal complications afterwards, research has found.
Drugs such as Ozempic and Wegovy reduce the risk of the tissue damage that affects up to half of the 100,000 people a year in the UK who suffer a heart attack, according to the study.
The researchers, experts in heart health, concluded that GLP-1 weight-loss drugs “could offer a promising new therapeutic approach for improving heart attack recovery”.
The drugs are already known to lower the risk of someone having a heart attack or stroke. But this is the first time they have been repurposed to treat this common complication of a heart attack.
Dr Svetlana Mastitskaya, the study’s lead author, said the results were so encouraging that they could help pave the way for paramedics giving the drugs to heart attack patients they treat.
“In nearly half of all heart attack patients, tiny blood vessels within the heart remain narrowed, even after the main artery is cleared during emergency treatment.
“This results in a complication known as ‘no-reflow’, where blood is unable to reach certain parts of the heart tissue”, said Mastitskaya, a senior lecturer at Bristol University’s medical school.
No-reflow increases the risk of someone dying or being readmitted to hospital for further treatment for heart failure within a year of their heart attack. “But our latest findings are surprising in that we have found GLP-1 drugs may prevent this problem,” she added.
However, the results are based on animal model trials so further studies involving humans would need to occur and show the same benefits before GLP-1s could be used on people.
The British Heart Foundation funded the trial, which also involved experts from University College London. The results are published in Nature Communications.
The study co-lead Prof David Attwell of UCL said GLP-1s offer “a potentially life-saving solution” for those who experience no-reflow.
Mastitskaya told PA Media that “the drugs can be given by paramedics attending the patient even on the way to the hospital and/or during surgical reopening of the occluded artery”, though added that clinical trials were needed first.
It is unknown why no-reflow happens so often after a heart attack, despite treatment.

“This research suggests that mimicking the action of the GLP‑1 hormone may have potential to improve blood flow through microvessels and perhaps one day could have a role in heart attack treatment. This will require detailed studies in humans and clinical trials first,” said Prof Bryan Williams, the BHF’s chief scientific and medical officer.
“Large clinical trials of GLP‑1 medicines, such as Ozempic and Wegovy, have shown benefits on heart health beyond weight loss. But how they produce these effects has remained unclear. This fascinating study offers one possible explanation, suggesting that they may help to improve blood flow through the heart’s smallest blood vessels.”
A free press for a fairer world
Our collective global future is being rapidly reshaped by political, technological and corporate forces focused on the accumulation of power and money.
As other news outlets have shrunk their international reporting presence, in the past few years we have appointed new correspondents in the Caribbean, South America and Africa, greatly expanded our European coverage with a new digital edition, and continued to grow the geographic scope of our coverage in our bases in the UK, US and Australia.
This international lens, paired with expert local knowledge, puts us in a prime position to tell stories to, and from, the world. It’s a commitment to a broader outlook that comes at a time when other news organisations are doing the opposite.
This is no time to turn inwards. Independent journalism protects democracy globally and helps set the truth free. Please choose to support it today.
There is too much happening now to start looking inwards. The world can’t wait.
And there are two crucial reasons why the Guardian is able to be more global at this crucial moment, not less.
One: we are owned by the Scott Trust, which exists solely to safeguard the independence of our journalism in perpetuity.
The second reason is just as vital: the majority of our journalism is now funded by people like you from Vietnam. This direct support from our audience inspires us: to serve you as fully as we can, to bring you clarity in a chaotic world, and to bring you truth without caveat or compromise.
